NPPA caps on trade margin of 42 Non Scheduled Cancer Drugs

The NPPA has also brought 106 non-scheduled anti-diabetic and cardiovascular drugs under price control

NPPA Price of drugs

Last Updated on August 12, 2021 by The Health Master

Putting a cap on the trade margin of 42 select non-scheduled anti-cancer medicines by the National Pharmaceutical Pricing Authority (NPPA) resulted in reduction of up to 90 per cent in the maximum retail price of 526 brands of these drugs, Parliament was informed on Tuesday.

This was done under the ‘Trade Margin Rationalisation’ (TMR) approach, Minister of Chemicals and Fertilisers Mansukh Mandaviya said in a written reply to a question in the Lok Sabha.

The NPPA has also brought 106 non-scheduled anti-diabetic and cardiovascular drugs under price control by invoking extraordinary powers in public interest, he added.

“The total annual savings on account of revision of ceiling prices of medicines under the National List of Essential Medicines (NLEM), price control of anti-diabetic and cardiovascular, fixation of ceiling price of stents, knee implants and capping of TMR on anti-cancer are estimated to the tune of Rs 12,500 crore,” Mandaviya said.

The NPPA monitors the ceiling price of the scheduled formulations to ensure that the MRP of such formulations are within the range of ceiling price.

It also monitors non-scheduled formulations to ensure that their MRP does not increase by more than 10 percent during the preceding 12 months, he added.

Latest notifications – DPCO /NPPA

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

NPPA fixes retail price of 6 formulations

NPPA approves retail prices of these 25 New Drugs

NPPA seeks market data from these Medical Devices Mfrs and importers

NPPA asks Importers & Mfrs of 5 Medical Devices to submit data every quarter

NPPA fixes ceiling prices of 355 Medicines and 882 Formulations

NPPA releases revised price list of 631 Medical Devices

Latest Notifications regarding Pharmaceuticals

India and Pharmacy Education: Chapter: 4

NPPA fixes retail price of 6 formulations

High Court divided over interpretation of search provision

Demand to amend Rule 64(1) of Drugs & Cosmetics Rules

This is major side effect of rampant use of Steroids

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner